CoChat

Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study

Open access
Oscarsson, Jan, Önnerhag, Kristina, Risérus, Ulf, Sundén, Mattias, Johansson, Lars, Jansson, Per-Anders, Moris, Linda, Nilsson, Peter M., Eriksson, Jan W., Lind, Lars · 2018 · Journal of Clinical Lipidology
Cited by 112

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Treatment with omega-3 fatty acids and fenofibrates reduces serum triglyceride levels, but few studies have compared the effect of these agents on liver fat. OBJECTIVE: The aim of the EFFECT I trial (NCT02354976) was to determine the effects of free omega-3 carboxylic acids (OM-3CA) and fenofibrate on liver fat in overweight or obese individuals with non-alcoholic fatty liver disease and hypertriglyceridemia. METHODS: Seventy-eight patients were randomized to receive oral doses of 4 g OM-3CA (n = 25), 200 mg fenofibrate (n = 27), or placebo (n = 26) for 12 weeks in a double-blind, parallel-group study. Liver proton density fat fraction (PDFF) and volume, pancreas volume, and adipose tissue volumes were assessed by magnetic resonance imaging. RESULTS: Changes in liver PDFF at 12 weeks were not significantly different across treatment groups (relative changes from baseline: placebo, +4%; OM-3CA, -2%; and fenofibrate, +17%). The common PNPLA3 genetic polymorphism (I148M) did not significantly influence the effects of OM-3CA or fenofibrate on liver PDFF. Fenofibrate treatment significantly increased liver and pancreas volumes vs placebo treatment, and the changes in liver and pancreas volumes were positively correlated (rho 0.45, P = .02). Total liver fat volume increased significantly in patients using fenofibrate vs OM-3CA (+23% vs -3%, P = .04). Compared with OM-3CA, fenofibrate increased total liver fat and liver volume. Serum triglycerides decreased with OM-3CA (-26%, P = .02) and fenofibrate (-38%, P < .001) vs placebo. In contrast to OM-3CA, fenofibrate reduced plasma docosahexaenoic acid levels and increased plasma acetylcarnitine and butyrylcarnitine levels, estimated delta-9 desaturase activity and the concentration of urine F2-isoprostanes. CONCLUSIONS: OM-3CA and fenofibrate reduced serum triglycerides but did not reduce liver fat. Fenofibrate increased total liver volume and total liver fat volume vs OM-3CA, indicating a complex effect of fenofibrate on human hepatic lipid metabolism.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacl.2018.08.003

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Research works printed but not linked: 41

  1. Karlson, 2016, A VOYAGER meta-analysis of the impact of statin therapy on low-density lipoprotein cholesterol and triglyceride levels in patients with hypertriglyceridemia, Am J Cardiol, 117, 1444, 10.1016/j.amjcard.2016.02.011 · DOI · Paper page
  2. 2016, Vol. 2017
  3. Patel, 2016, Effects of eicosapentaenoic acid and docosahexaenoic acid on lipoproteins in hypertriglyceridemia, Curr Opin Endocrinol Diabetes Obes, 23, 145, 10.1097/MED.0000000000000233 · DOI
  4. Davidson, 2016, The future of n-3 polyunsaturated fatty acid therapy, Curr Opin Lipidol, 27, 570, 10.1097/MOL.0000000000000353 · DOI
  5. Oscarsson, 2017, Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review, Lipids Health Dis, 16, 149, 10.1186/s12944-017-0541-3 · DOI · Paper page
  6. Cussons, 2009, Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy, J Clin Endocrinol Metab, 94, 3842, 10.1210/jc.2009-0870 · DOI · Paper page
  7. Vega, 2008, Effects of N-3 fatty acids on hepatic triglyceride content in humans, J Investig Med, 56, 780, 10.2310/JIM.0b013e318177024d · DOI · Paper page
  8. Scorletti, 2014, Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the WELCOME* study, Hepatology, 60, 1211, 10.1002/hep.27289 · DOI · Paper page
  9. Keating, 2011, Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus, Am J Cardiovasc Drugs, 11, 227, 10.2165/11207690-000000000-00000 · DOI
  10. Balasubramanian, 2010, Combination peroxisome proliferator-activated receptor gamma and alpha agonist treatment in type 2 diabetes prevents the beneficial pioglitazone effect on liver fat content, Diabet Med, 27, 150, 10.1111/j.1464-5491.2009.02906.x · DOI
  11. Cree, 2007, Plasma triglycerides are not related to tissue lipids and insulin sensitivity in elderly following PPAR-alpha agonist treatment, Mech Ageing Dev, 128, 558, 10.1016/j.mad.2007.08.001 · DOI
  12. Bajaj, 2007, Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus, Diabetologia, 50, 1723, 10.1007/s00125-007-0698-9 · DOI
  13. Risérus, 2008, Activation of peroxisome proliferator-activated receptor (PPAR) delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men, Diabetes, 57, 332, 10.2337/db07-1318 · DOI · Paper page
  14. Harano, 2006, Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver, Liver Int, 26, 613, 10.1111/j.1478-3231.2006.01265.x · DOI
  15. Huang, 2012, Sustained activation of PPARalpha by endogenous ligands increases hepatic fatty acid oxidation and prevents obesity in ob/ob mice, FASEB J, 26, 628, 10.1096/fj.11-194019 · DOI · Paper page
  16. Waterman, 2002, Differential effects of fenofibrate or simvastatin treatment of rats on hepatic microsomal overt and latent diacylglycerol acyltransferase activities, Diabetes, 51, 1708, 10.2337/diabetes.51.6.1708 · DOI
  17. Edvardsson, 2006, PPARalpha activation increases triglyceride mass and adipose differentiation-related protein in hepatocytes, J Lipid Res, 47, 329, 10.1194/jlr.M500203-JLR200 · DOI
  18. Yan, 2014, Peroxisome proliferator-activated receptor alpha activation induces hepatic steatosis, suggesting an adverse effect, PLoS One, 9, e99245, 10.1371/journal.pone.0099245 · DOI
  19. Berglund, 2012, Three-dimensional water/fat separation and T2* estimation based on whole-image optimization – application in breathhold liver imaging at 1.5 T, Magn Reson Med, 67, 1684, 10.1002/mrm.23185 · DOI
  20. Schneider, 2012, NIH Image to ImageJ: 25 years of image analysis, Nat Methods, 9, 671, 10.1038/nmeth.2089 · DOI · Paper page
  21. Malmberg, 2017, SmartPaint: a tool for interactive segmentation of medical volume images, Comput Methods Biomech Biomed Eng Imaging Vis, 5, 36, 10.1080/21681163.2014.960535 · DOI
  22. Angulo, 2007, The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD, Hepatology, 45, 846, 10.1002/hep.21496 · DOI · Paper page
  23. Boberg, 1985, Platelet fatty acid composition in relation to fatty acid composition in plasma and to serum lipoprotein lipids in healthy subjects with special reference to the linoleic acid pathway, Clin Sci, 68, 581, 10.1042/cs0680581 · DOI · Paper page
  24. Gariot, 1983, Fenofibrate and human liver. Lack of proliferation of peroxisomes, Arch Toxicol, 53, 151, 10.1007/BF00302723 · DOI
  25. Gariot, 1987, Morphometric study of human hepatic cell modifications induced by fenofibrate, Metabolism, 36, 203, 10.1016/0026-0495(87)90177-6 · DOI
  26. Tailleux, 2012, Roles of PPARs in NAFLD: potential therapeutic targets, Biochim Biophys Acta, 1821, 809, 10.1016/j.bbalip.2011.10.016 · DOI · Paper page
  27. Kersten, 2014, Integrated physiology and systems biology of PPARalpha, Mol Metab, 3, 354, 10.1016/j.molmet.2014.02.002 · DOI · Paper page
  28. Koh, 2012, Significant differential effects of omega-3 fatty acids and fenofibrate in patients with hypertriglyceridemia, Atherosclerosis, 220, 537, 10.1016/j.atherosclerosis.2011.11.018 · DOI · Paper page
  29. Otto, 1996, Effects of n-3 fatty acids and fenofibrate on lipid and hemorrheological parameters in familial dysbetalipoproteinemia and familial hypertriglyceridemia, Metabolism, 45, 1305, 10.1016/S0026-0495(96)90252-8 · DOI
  30. Agheli, 1991, Effect of simvastatin and fenofibrate on the fatty acid composition of hypercholesterolaemic patients, Br J Clin Pharmacol, 32, 423, 10.1111/j.1365-2125.1991.tb03925.x · DOI
  31. Fernandez-Alvarez, 2011, Human SREBP1c expression in liver is directly regulated by peroxisome proliferator-activated receptor alpha (PPARalpha), J Biol Chem, 286, 21466, 10.1074/jbc.M110.209973 · DOI
  32. Yary, 2016, Serum n-6 polyunsaturated fatty acids, Delta5- and Delta6-desaturase activities, and risk of incident type 2 diabetes in men: the Kuopio Ischaemic heart disease risk factor study, Am J Clin Nutr, 103, 1337, 10.3945/ajcn.115.128629 · DOI
  33. Vessby, 1994, The risk to develop NIDDM is related to the fatty acid composition of the serum cholesterol esters, Diabetes, 43, 1353, 10.2337/diab.43.11.1353 · DOI · Paper page
  34. Gonzalez-Periz, 2009, Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins, Faseb J, 23, 1946, 10.1096/fj.08-125674 · DOI · Paper page
  35. Sun, 2016, Early prediction of developing type 2 diabetes by plasma acylcarnitines: a population-based study, Diabetes Care, 39, 1563, 10.2337/dc16-0232 · DOI · Paper page
  36. Xu, 2016, Liver and muscle contribute differently to the plasma acylcarnitine pool during fasting and exercise in humans, J Clin Endocrinol Metab, 101, 5044, 10.1210/jc.2016-1859 · DOI · Paper page
  37. Kobayashi, 2009, Effects of fenofibrate on plasma and hepatic transaminase activities and hepatic transaminase gene expression in rats, J Toxicol Sci, 34, 377, 10.2131/jts.34.377 · DOI
  38. Fernandez-Miranda, 2008, A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease, Dig Liver Dis, 40, 200, 10.1016/j.dld.2007.10.002 · DOI · Paper page
  39. Kei, 2014, Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia, Cardiovasc Ther, 32, 139, 10.1111/1755-5922.12072 · DOI
  40. Qin, 2015, Fish oil supplements lower serum lipids and glucose in correlation with a reduction in plasma fibroblast growth factor 21 and prostaglandin E2 in nonalcoholic fatty liver disease associated with hyperlipidemia: a randomized clinical trial, PLoS One, 10, e0133496, 10.1371/journal.pone.0133496 · DOI
  41. De Caterina, 2007, N-3 fatty acids in the treatment of diabetic patients: biological rationale and clinical data, Diabetes Care, 30, 1012, 10.2337/dc06-1332 · DOI · Paper page

Cited by

See all 112

Metadata

Authors
Oscarsson, J., Önnerhag, K., Risérus, U., Sundén, M., Johansson, L., Jansson, P.-A., Moris, L., Nilsson, P. M., Eriksson, J. W., & Lind, L.
Venue
Journal of Clinical Lipidology
Publisher
Elsevier BV
Published
2018-11
Volume
12
Issue
6
Pages
1390-1403.e4
ISSN
  • 1876-4789 (ISSN-L)
  • 1933-2874
OpenAlex
W2887902401
Cited by
112
References
21
FWCI
5.45
Type
journal article
Language
en
Open access
hybrid
Licence
Funders
AstraZeneca

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study. https://app.cochat.ai/papers/10.1016/j.jacl.2018.08.003
The paper
Oscarsson, J., Önnerhag, K., Risérus, U., Sundén, M., Johansson, L., Jansson, P.-A., Moris, L., Nilsson, P. M., Eriksson, J. W., & Lind, L. (2018). Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study. Journal of Clinical Lipidology. https://doi.org/10.1016/j.jacl.2018.08.003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.